The repeat order follows the customer’s thorough evaluation of UnoMeter Safeti MAX in clinical use, including its innovative product features and the potential clinical and health-economic benefits of the solution. Following the successful evaluation, the customer has chosen to place a new order, providing an important early commercial validation of both the product and the underlying patented technology.
UnoMeter Safeti MAX represents an important innovation within urine measurement and is designed to improve clinical workflow, patient safety and ease of use. The product incorporates proprietary and patented technology, differentiating it from traditional urine measurement solutions.
The repeat order represents an important milestone in the commercialization of UnoMeter Safeti MAX. Observe Medical is experiencing good traction following the product launch, with increasing customer interest and a growing pipeline of commercial opportunities.
“We are very pleased to see a customer move from a thorough evaluation of UnoMeter Safeti MAX to placing a repeat order. This is particularly important to us, as the decision follows hands-on testing of the product and its unique patented technology in a clinical setting. We see this as an encouraging early validation of the value proposition and an important step in building recurring commercial demand for UnoMeter Safeti MAX,” said Jørgen Mann, CEO of Observe Medical ASA.
With UnoMeter Safeti MAX successfully launched and now generating repeat orders following customer evaluations, Observe Medical continues to focus on converting its growing pipeline and customer interest into further commercial orders and broader market adoption.
For further information, please contact:
Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.